Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
586 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-01-01
Study Completion Date
2024-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of the TRVD™ System in ADHF
NCT03621436
Acute Heart Failure
Congestive Heart Failure
Heart Failure, Congestive
TERMINATED
NA
Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy
NCT00402376
Heart Failure
TERMINATED
PHASE4
Rivet PVS Therapy in Group 2 PH-HFpEF Canada
NCT05332873
Heart Failure
Pulmonary Hypertension
WITHDRAWN
NA
Rivet PVS Therapy in Group 2 PH-HFpEF
NCT05205265
Heart Failure
Pulmonary Hypertension
WITHDRAWN
NA
Mitral Regurgitation Treatment in Advanced Heart Failure
NCT05292716
Heart Failure
Mitral Regurgitation
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. BACKGROUND AND SIGNIFICANCE
Precise assessment of volume status is essential in diagnosis and management of diuretic therapy in patients hospitalized for heart failure (HF). Unfortunately, no clear guidelines are present for in-hospital management of congestion. Consequently, nearly half of the patients hospitalized for congestive HF are discharged with persistent congestion. This contributes to high rates of readmission and mortality.
Recently, it has been shown that a simple assessment of peripheral venous pressure (PVP) demonstrates a high correlation with central venous pressure (CVP), indicating that PVP may be useful in the standard bedside clinical assessment of volume status in HF patients to help guiding decongestive therapy.
II. THE HYPOTHESIS
The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.
III. METHODS
1. Application for Institutional Review Board (IRB)/Ethics board approval The study will be conducted at Marmara University, Pendik Training and Research Hospital, Cerrahpaşa University Hospital, Darıca Farabi Training and Research Hospital, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, and Başaksehir Çam \& Sakura Hospital, all of which are tertiary referral centers for heart failure. An IRB/Ethics board approval will be obtained from the local ethics boards.
2. Study population Patients \>18 years old who were admitted with a de novo or decompensated chronic HF will be enrolled. Patients will be included regardless of ejection fraction or etiology of HF, but these will be noted as baseline variables. All patients or legal surrogate decision makers will be requested to provide a written informed consent prior to enrollment. Patients who does not consent, those with upper extremity venous pathology, those with a baseline creatinine level equal to or above 3.5 mg/dL, those with severe stenotic valvular disease and hypertrophic cardiomyopathy will be excluded.
3. Centers and Personnel The study will be undertaken at Marmara University, Pendik Training and Research Hospital, Cerrahpaşa University Hospital, Darıca Farabi Training and Research Hospital, Başaksehir Çam \& Sakura Hospital and Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital.
4. Data Collection The study will start at Marmara University, Pendik Training and Research Hospital, Başaksehir Çam \& Sakura Hospital, Cerrahpaşa University Hospital, Darıca Farabi Training and Research Hospital and Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, at January 1, 2022 (after the approvals from the local ethical committees are obtained).
Baseline variables Baseline variables will be collected via chart review and entered to the study form (see below).
Procedures A peripheral intravenous (IV) access, using an 18 to 22-gauge IV line, will be placed preferably to an upper extremity vein before enrollment. This line will be used to draw blood samples first. After blood samples were collected the subjects will be randomized to standard or PVP guided therapy groups. Randomization will be done using a computer-generated random allocation list. The details of demographic characteristics, symptoms, physical examination findings and drug list will be noted to a standard study form (see below).
A routine electrocardiogram and echocardiogram (including stroke volume calculated form left ventricular outflow tract size and velocity-time integral; diastolic mitral flow Doppler and mitral annular tissue Doppler measurements, inferior vena cava diameter and respiratory variation) and an 8-point lung ultrasound for total B-line count will be performed at the earliest convenience and before discharge.
After the blood samples were collected, line will be flushed carefully. PVP will be obtained by transducing a peripheral intravenous line after zeroing at the phlebostatic axis. The phlebostatic axis will be accepted as the midpoint between the anterior and posterior surfaces of the chest at the level of the fourth intercostal space meets with sternum, which is assumed to be correlated with the mid-level of the right atrium. The patient's arm will be placed parallel to the patient such that the position of the peripheral IV to be at the phlebostatic axis. Continuity of the peripheral IV line with the central venous system will be confirmed by demonstrating augmentation of the venous pressure waveform using manual or tourniquet circumferential occlusion of the extremity proximal to the catheter. If the pressure waveform failed to augment appropriately, data will not be collected, and the patient will be documented for study purposes as a technique failure. Daily fluid intake and output, weight, and biochemistry measurements, as required, will be done.
The patients in whom the first and the predischarge PVP cannot be measured due to technical issues (unable to provide upper extremity IV access, unable to confirm augmentation test) will be excluded from the study. Also, the patients requiring in-hospital intubation, high-dose inotrope or vasopressor infusion (≥10 mcg.kg-1.min-1 dopamine, dobutamine or equivalent), intraaortic balloon support, dialysis or venovenous ultrafiltration will be excluded from the study (but these patients will be included in the in-hospital analyses).
In hospital diuretic treatment will be guided by European Society of Cardiology guidelines (see below for algorithm). In standard therapy arm, the treatment and the decision of discharge will be left to physicians' discretion. In the PVP-guided arm, a PVP ≤9 mmHg will be targeted before discharge.
Outcomes The primary outcome of the study is the composite endpoint of all-cause mortality, all-cause hospitalization and all-cause emergency department visits. The secondary outcomes will include cardiovascular mortality, HF-related hospitalization, HF-related emergency department visits. These information on these outcomes will be obtained from national electronic database. The follow-up duration is planned to be limited to one-year.
Summary of patient enrollment criteria
Inclusion criteria
* Hospitalization for heart failure (de novo or decompensated chronic heart failure)
* Age \>18
Exclusion criteria
* A prior history of upper extremity venous disease
* Serum creatinine ≥ 3.5 mg/dL
* Severe stenotic valvular disease
* Hypertrophic obstructive cardiomyopathy
Exclusion from long term follow-up after randomization
* Unable to obtain first and pre-discharge PVP due to technical issues (unable to access an upper extremity vein, negative augmentation test)
* In-hospital intubation
* Need for high-dose vasopressor or inotrope medications (≥10 mcg.kg.-1.min-1 dopamine, dobutamine or equivalent)
* Need for intra-aortic balloon pump support
* In-hospital need for dialysis or veno-venous ultrafiltration
Predefined secondary analyses
There will be substudies from the same cohort utilizing other analyses, as defined below:
* The correlation between predischarge PVP and long-term outcomes. A multivariable analysis will also be executed for predicting the primary end point.
* The correlation between the change in PVP during hospital stay and long-term outcomes. A multivariable analysis will also be executed for predicting the primary end point.
* The correlation between the change in PVP during hospital stay and worsening renal function, need for dialysis or veno-venous ultrafiltration.
* The comparison of the two arms in terms of worsening renal function, need for dialysis or veno-venous ultrafiltration.
* The comparison of the two arms in terms of EVEREST congestion score.
* The comparison of the two arms in terms of the days in hospital.
* The comparison of the two arms in terms of the number of repeat hospitalization.
* The relationship between venous compliance and short and long-term outcomes.
Estimated number of subjects to be submitted:
It is estimated that the enrollment of 586 participants would provide the study with a statistical power of 95% to detect a relative excess rate of 10% in primary outcome (peripheral pressure guided group 20% versus standard approach 30%) with the use of a two-sided test at the 0.05 level. Accordingly, it is expected to enroll at least 600 patients in a one-year enrollment period.
Statistical Analysis Baseline characteristics will be summarized using standard descriptive statistics. Comparisons of relevant parameters between groups will be performed by chi-square, Fisher's exact test, Mann-Whitney U, Kruskal-Wallis H test, one-way ANOVA and student t-test, as appropriate. Patients with missing values will be excluded pairwise from analyses. Kaplan-Meier analysis will be performed to determine the cumulative long-term mortality and composite outcome rates in subgroups. The mortality across groups will be compared using log-rank test. A Cox-regression model will be used to perform a survival analysis according to pre-discharge peripheral venous pressure and composite outcome. Baseline characteristics with a P value of 0.05 or less in the univariate analysis will be included and a step-down procedure will be applied for selection of final covariates. Statistical analyses will be performed with Statistical Package for Social Sciences (SPSS, version 24.0; SPSS Inc., Chicago, IL) and MedCalc Software (version 18.2.1 \[Evaluation version\]; MedCalc Software, Ostend, Belgium).
Precise assessment of volume status is essential in diagnosis and management of diuretic therapy in patients hospitalized for heart failure (HF). Unfortunately, no clear guidelines are present for in-hospital management of congestion. Consequently, nearly half of the patients hospitalized for congestive HF are discharged with persistent congestion. This contributes to high rates of readmission and mortality.
Recently, it has been shown that a simple assessment of peripheral venous pressure (PVP) demonstrates a high correlation with central venous pressure (CVP), indicating that PVP may be useful in the standard bedside clinical assessment of volume status in HF patients to help guiding decongestive therapy.
II. THE HYPOTHESIS
The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.
III. METHODS
1. Application for Institutional Review Board (IRB)/Ethics board approval The study will be conducted at Marmara University, Pendik Training and Research Hospital, Cerrahpaşa University Hospital, Darıca Farabi Training and Research Hospital, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, and Başaksehir Çam \& Sakura Hospital, all of which are tertiary referral centers for heart failure. An IRB/Ethics board approval will be obtained from the local ethics boards.
2. Study population Patients \>18 years old who were admitted with a de novo or decompensated chronic HF will be enrolled. Patients will be included regardless of ejection fraction or etiology of HF, but these will be noted as baseline variables. All patients or legal surrogate decision makers will be requested to provide a written informed consent prior to enrollment. Patients who does not consent, those with upper extremity venous pathology, those with a baseline creatinine level equal to or above 3.5 mg/dL, those with severe stenotic valvular disease and hypertrophic cardiomyopathy will be excluded.
3. Centers and Personnel The study will be undertaken at Marmara University, Pendik Training and Research Hospital, Cerrahpaşa University Hospital, Darıca Farabi Training and Research Hospital, Başaksehir Çam \& Sakura Hospital and Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital.
4. Data Collection The study will start at Marmara University, Pendik Training and Research Hospital, Başaksehir Çam \& Sakura Hospital, Cerrahpaşa University Hospital, Darıca Farabi Training and Research Hospital and Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, at January 1, 2022 (after the approvals from the local ethical committees are obtained).
Baseline variables Baseline variables will be collected via chart review and entered to the study form (see below).
Procedures A peripheral intravenous (IV) access, using an 18 to 22-gauge IV line, will be placed preferably to an upper extremity vein before enrollment. This line will be used to draw blood samples first. After blood samples were collected the subjects will be randomized to standard or PVP guided therapy groups. Randomization will be done using a computer-generated random allocation list. The details of demographic characteristics, symptoms, physical examination findings and drug list will be noted to a standard study form (see below).
A routine electrocardiogram and echocardiogram (including stroke volume calculated form left ventricular outflow tract size and velocity-time integral; diastolic mitral flow Doppler and mitral annular tissue Doppler measurements, inferior vena cava diameter and respiratory variation) and an 8-point lung ultrasound for total B-line count will be performed at the earliest convenience and before discharge.
After the blood samples were collected, line will be flushed carefully. PVP will be obtained by transducing a peripheral intravenous line after zeroing at the phlebostatic axis. The phlebostatic axis will be accepted as the midpoint between the anterior and posterior surfaces of the chest at the level of the fourth intercostal space meets with sternum, which is assumed to be correlated with the mid-level of the right atrium. The patient's arm will be placed parallel to the patient such that the position of the peripheral IV to be at the phlebostatic axis. Continuity of the peripheral IV line with the central venous system will be confirmed by demonstrating augmentation of the venous pressure waveform using manual or tourniquet circumferential occlusion of the extremity proximal to the catheter. If the pressure waveform failed to augment appropriately, data will not be collected, and the patient will be documented for study purposes as a technique failure. Daily fluid intake and output, weight, and biochemistry measurements, as required, will be done.
The patients in whom the first and the predischarge PVP cannot be measured due to technical issues (unable to provide upper extremity IV access, unable to confirm augmentation test) will be excluded from the study. Also, the patients requiring in-hospital intubation, high-dose inotrope or vasopressor infusion (≥10 mcg.kg-1.min-1 dopamine, dobutamine or equivalent), intraaortic balloon support, dialysis or venovenous ultrafiltration will be excluded from the study (but these patients will be included in the in-hospital analyses).
In hospital diuretic treatment will be guided by European Society of Cardiology guidelines (see below for algorithm). In standard therapy arm, the treatment and the decision of discharge will be left to physicians' discretion. In the PVP-guided arm, a PVP ≤9 mmHg will be targeted before discharge.
Outcomes The primary outcome of the study is the composite endpoint of all-cause mortality, all-cause hospitalization and all-cause emergency department visits. The secondary outcomes will include cardiovascular mortality, HF-related hospitalization, HF-related emergency department visits. These information on these outcomes will be obtained from national electronic database. The follow-up duration is planned to be limited to one-year.
Summary of patient enrollment criteria
Inclusion criteria
* Hospitalization for heart failure (de novo or decompensated chronic heart failure)
* Age \>18
Exclusion criteria
* A prior history of upper extremity venous disease
* Serum creatinine ≥ 3.5 mg/dL
* Severe stenotic valvular disease
* Hypertrophic obstructive cardiomyopathy
Exclusion from long term follow-up after randomization
* Unable to obtain first and pre-discharge PVP due to technical issues (unable to access an upper extremity vein, negative augmentation test)
* In-hospital intubation
* Need for high-dose vasopressor or inotrope medications (≥10 mcg.kg.-1.min-1 dopamine, dobutamine or equivalent)
* Need for intra-aortic balloon pump support
* In-hospital need for dialysis or veno-venous ultrafiltration
Predefined secondary analyses
There will be substudies from the same cohort utilizing other analyses, as defined below:
* The correlation between predischarge PVP and long-term outcomes. A multivariable analysis will also be executed for predicting the primary end point.
* The correlation between the change in PVP during hospital stay and long-term outcomes. A multivariable analysis will also be executed for predicting the primary end point.
* The correlation between the change in PVP during hospital stay and worsening renal function, need for dialysis or veno-venous ultrafiltration.
* The comparison of the two arms in terms of worsening renal function, need for dialysis or veno-venous ultrafiltration.
* The comparison of the two arms in terms of EVEREST congestion score.
* The comparison of the two arms in terms of the days in hospital.
* The comparison of the two arms in terms of the number of repeat hospitalization.
* The relationship between venous compliance and short and long-term outcomes.
Estimated number of subjects to be submitted:
It is estimated that the enrollment of 586 participants would provide the study with a statistical power of 95% to detect a relative excess rate of 10% in primary outcome (peripheral pressure guided group 20% versus standard approach 30%) with the use of a two-sided test at the 0.05 level. Accordingly, it is expected to enroll at least 600 patients in a one-year enrollment period.
Statistical Analysis Baseline characteristics will be summarized using standard descriptive statistics. Comparisons of relevant parameters between groups will be performed by chi-square, Fisher's exact test, Mann-Whitney U, Kruskal-Wallis H test, one-way ANOVA and student t-test, as appropriate. Patients with missing values will be excluded pairwise from analyses. Kaplan-Meier analysis will be performed to determine the cumulative long-term mortality and composite outcome rates in subgroups. The mortality across groups will be compared using log-rank test. A Cox-regression model will be used to perform a survival analysis according to pre-discharge peripheral venous pressure and composite outcome. Baseline characteristics with a P value of 0.05 or less in the univariate analysis will be included and a step-down procedure will be applied for selection of final covariates. Statistical analyses will be performed with Statistical Package for Social Sciences (SPSS, version 24.0; SPSS Inc., Chicago, IL) and MedCalc Software (version 18.2.1 \[Evaluation version\]; MedCalc Software, Ostend, Belgium).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Heart Failure
Edema
Volume Overload
Heart Failure，Congestive
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Two arms with a standard care control group and a peripheral pressure guided intervention group
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PVP-Guided
Peripheral venous pressure guided therapy arm
Group Type
EXPERIMENTAL
Diuretic therapy
Intervention Type
DRUG
Standard diuretic therapy according to the current guidelines
Control
Standard medical therapy arm
Group Type
ACTIVE_COMPARATOR
Diuretic therapy
Intervention Type
DRUG
Standard diuretic therapy according to the current guidelines
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diuretic therapy
Standard diuretic therapy according to the current guidelines
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalization for heart failure (de novo or decompensated chronic heart failure)
* Age \>18
* Age \>18
Exclusion Criteria
* A prior history of upper extremity venous disease
* Serum creatinine ≥ 3.5 mg/dL
* Severe stenotic valvular disease
* Hypertrophic obstructive cardiomyopathy
Exclusion from long term follow-up after randomization
* Unable to obtain first and pre-discharge PVP due to technical issues (unable to access an upper extremity vein, negative augmentation test)
* In-hospital intubation
* Need for high-dose vasopressor or inotrope medications (≥10 mcg.kg.-1.min-1 dopamine, dobutamine or equivalent)
* Need for intra-aortic balloon pump support
* In-hospital need for dialysis or veno-venous ultrafiltration
* Serum creatinine ≥ 3.5 mg/dL
* Severe stenotic valvular disease
* Hypertrophic obstructive cardiomyopathy
Exclusion from long term follow-up after randomization
* Unable to obtain first and pre-discharge PVP due to technical issues (unable to access an upper extremity vein, negative augmentation test)
* In-hospital intubation
* Need for high-dose vasopressor or inotrope medications (≥10 mcg.kg.-1.min-1 dopamine, dobutamine or equivalent)
* Need for intra-aortic balloon pump support
* In-hospital need for dialysis or veno-venous ultrafiltration
Minimum Eligible Age
18 Years
Maximum Eligible Age
99 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
OTHER
Sponsor Role
collaborator
Başakşehir Çam & Sakura City Hospital
OTHER_GOV
Sponsor Role
collaborator
Marmara University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emre K Aslanger, Assoc. Prof.
Role: STUDY_DIRECTOR
Marmara University
Dursun Akaslan, MD
Role: PRINCIPAL_INVESTIGATOR
Marmara University
Özlem Yıldırımtürk, Prof.
Role: PRINCIPAL_INVESTIGATOR
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Duygu İnan, MD
Role: PRINCIPAL_INVESTIGATOR
Basaksehir Cam & Sakura State Hospital
Yelda Saltan, MD
Role: PRINCIPAL_INVESTIGATOR
Basaksehir Cam & Sakura State Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Basaksehir Cam & Sakura State Hospital
Istanbul, , Turkey (Türkiye)
Site Status
RECRUITING
Cerrahpasa University
Istanbul, , Turkey (Türkiye)
Site Status
RECRUITING
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Site Status
RECRUITING
Marmara University Pendik Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Site Status
RECRUITING
Darıca Farabi Training and Research Hospital
Kocaeli, , Turkey (Türkiye)
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Turkey (Türkiye)
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Duygu İnan, MD
Role: primary
Ali U Soysal, MD
Role: primary
Özlem Yıldırımtürk, Prof
Role: primary
Emre K Aslanger, Assoc. Prof.
Role: primary
Ebru Golcuk Onder, Assoc. Prof.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MU-2022-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
HF Patients With LVADs Being Treated With SGLT2i
NCT05278962
COMPLETED
PHASE4
Optimization of Heart Failure (HF) Medical Therapy After Transcatheter Valve Intervention (TVI) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT06667128
NOT_YET_RECRUITING
NA
Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
NCT00751972
COMPLETED
NA
FAST PV and mGFR™ Technology in Congestive Heart Failure
NCT03808948
COMPLETED
NA
LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients
NCT04768322
RECRUITING
NA
Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples
NCT00734045
COMPLETED
Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
NCT03279861
WITHDRAWN
PHASE4
Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions
NCT02003040
UNKNOWN
VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00490321
UNKNOWN
PHASE3
Enhanced External Counterpulsation
NCT01355315
COMPLETED
Nitric Oxide, GeNO Nitrosyl Delivery System
NCT01165047
COMPLETED
PHASE2
Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure
NCT02254382
TERMINATED
NA
Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure
NCT00834145
UNKNOWN
NA
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
NCT01953874
TERMINATED
NA
Endothelial Function and Circulating Microparticle in Patients Under LVAD Support
NCT03923413
COMPLETED
Monitoring Outpatient Blood VolumE in Heart Failure
NCT04660396
COMPLETED
Impella CP With VA ECMO for Cardiogenic Shock
NCT03431467
TERMINATED
NA
Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure
NCT01001312
TERMINATED
PHASE4
Study of Percutaneous Renal Artery Intervention for Patient With Heart Failure
NCT01403714
WITHDRAWN
NA
Ventricular Assist Device (VAD) Research Registry and Blood Sub-Study
NCT05637242
TERMINATED
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management
NCT01452802
COMPLETED
Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea
NCT04915924
COMPLETED
NA
Outcomes of a Novel Magnetically Levitated LVAD: a Multicenter Analysis
NCT06596499
COMPLETED
Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation
NCT02387112
UNKNOWN
NA
Adaptive Servo-Ventilation In Acute Heart Failure Patients Protecting the Heart and Kidneys
NCT02796638
UNKNOWN
NA